Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Talha BadarAniko SzaboShira DinnerMichaela LiedtkeMadelyn BurkartRory M ShallisIlana R YurkiewiczEric KuoMuhammad Ali KhanSuresh BalasubramanianJay YangMehrdad HefaziNikolai A PodoltsevAnand Ashwin PatelEmily CurranAmy WangShukaib ArslanIbrahim AldossCaitlin SiebenallerRyan J MattisonMark R LitzowMartha WadleighAnjali S AdvaniEhab AtallahPublished in: Cancer (2020)
Although the limited power of this study to detect a significant difference between subgroups is acknowledged, the data suggest that blinatumomab and InO may have comparable efficacy as a first or second NA therapy in RR ALL.